METHOD FOR MONITORING SERUM CONCENTRATIONS OF BEDAQUILINE FOR ASSESSING EFFECTIVENESS OF ANTI-TUBERCULOSIS CHEMOTHERAPY Russian patent published in 2024 - IPC G01N33/94 G01N33/49 G01N1/28 A61K31/47 A61K31/00 A61P31/06 

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to pulmonology, and can be used for monitoring serum concentrations of Bedaquiline for assessing the effectiveness of anti-tuberculosis chemotherapy. Anti-tuberculosis chemotherapy is carried out in the amount of: Bedaquiline 0.4 mg once day for 14 days, then 0.2 mg 3 times a week, Linezolid 0.6 mg once a day, Moxifloxacin 0.4 mg once a day, Cycloserine 0.25 mg 3 times a day, Pyrazinamide 0.5 mg 3 times a day, Amikacin 1.0 g once a day. Blood is sampled for a pharmacokinetic study, which includes three procedures, in the first of which blood is sampled on the day of the beginning of Bedaquiline intake at six time points at 8:00, 11:00, 14:00, 17:00, 21:00, 21:00, in the second, blood is sampled on the fourteenth day from the day of taking Bedaquiline at five time points at 8:00, 14:00, 17:00, 19:00, 21:00, in the third, blood is sampled on the eighty-fourth day from the day of the beginning of Bedaquiline intake at five time points at 8:00, 14:00, 17:00, 19:00, 21:00. During each blood sampling after taking into a test tube, it is smoothly turned 6 times for blood mixing, placed in rack for 45 minutes in an upright position at room temperature, centrifugation is carried out for 10 minutes at 3,000 rpm, the test tube is placed in a vertical position and placed in a refrigerator for use. Concentration of Bedaquiline in the sample is determined in mcg/l. If the serum concentration of Bedaquiline is more than or equal to 0.84 mcg/l, the anti-tuberculosis chemotherapy is considered to be effective.

EFFECT: method provides the possibility of increasing the accuracy of assessing the effectiveness of antituberculous chemotherapy by determining the dynamics of serum concentrations of Bedaquiline in order to ensure correction of the dose of Bedaquiline for the entire period of patient's treatment.

1 cl, 4 dwg, 2 ex